Drug General Information (ID: DDIADBQGW5)
Drug Name			Warfarin		Drug Info		Testolactone		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Anticoagulants				Antineoplastics
Structure

Mechanism of Warfarin-Testolactone Interaction (Severity Level: Moderate)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Warfarin				Testolactone
Mechanism		Risk of bleeding Anticoagulant				Risk of bleeding Antiplatelet effects
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Warfarin and Testolactone

Recommended Action
Management		During concomitant therapy, the INR and/or PT should be monitored frequently and anticoagulant dosage adjusted accordingly, particularly following initiation or discontinuation of testolactone in patients who are stabilized on their anticoagulation regimen. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.

References
1	de Oya JC, del Rio A, Noya M, Villanueva A "Decreased anticoagulant tolerance with oxymetholone in paroxysmal nocturnal haemoglobinuria." Lancet 2 (1971): 259. [PMID: 4104789]
2	Edwards MS, Curtis JR "Decreased anticoagulant tolerance with oxymetholone." Lancet 2 (1971): 221. [PMID: 4104889]
3	Ekert H, Muntz RH, Colebatch JH "Decreased anticoagulant tolerance with oxymetholone." Lancet 2 (1971): 609-10. [PMID: 4106131]
4	Goulbourne IA, Macleod DA "An interaction between danazol and warfarin: case report." Br J Obstet Gynaecol 88 (1981): 950-1. [PMID: 7272269]
5	Husted S, Andreasen F, Foged L "Increased sensitivity to phenprocoumon during methyltestosterone therapy." Eur J Clin Pharmacol 10 (1976): 209-16.
6	Longridge RG, Gillam PM, Barton GM "Decreased anticoagulant tolerance with oxymetholone." Lancet 2 (1971): 90. [PMID: 4103994]
7	Lorentz SM, Weibert RT "Potentiation of warfarin anticoagulation by topical testosterone ointment." Clin Pharm 4 (1985): 333-5. [PMID: 4006400]
8	Meeks ML, Mahaffey KW, Katz MD "Danazol increases the anticoagulant effect of warfarin." Ann Pharmacother 26 (1992): 641-2. [PMID: 1591422]
9	Murakami M, Odake K, Matsuda T, Onchi K, Umeda T, Nishino T "Effects of anabolic steroids on anticoagulant requirements." Jpn Circ J 29 (1965): 243-50. [PMID: 14311825]
10	Product Information. Teslac (testolactone). Bristol-Myers Squibb, Princeton, NJ.
11	Middleton T, Turner L, Fennell C, et al. Complications of injectable testosterone undecanoate in routine clinical practice.?Eur J Endocrinol. 2015;172(5):511-517. [PMID: 25637074]
12	Robinson BH, Hawkins JB, Ellis JE, Moore-Robinson M "Decreased anticoagulant tolerance with oxymetholone." Lancet 1 (1971): 1356. [PMID: 4103421]
13	Schrogie JJ, Solomon HM "The anticoagulant response to bishydroxycoumarin. II. The effect of D-thyroxine, clofibrate, and norethandrolone." Clin Pharmacol Ther 8 (1967): 70-7. [PMID: 4163172]
14	Shaw PW, Smith AM "Possible interaction of warfarin and stanozolol." Clin Pharm 6 (1987): 500-2. [PMID: 3690998]
15	Small M, Peterkin M, Lower GD, et al "Danazol and oral anticoagulants." Scott Med J 27 (1982): 331-2. [PMID: 7146883]
16	Wells PS, Holbrook AM, Crowther NR, Hirsh J "Interactions of warfarin with drugs and food." Ann Intern Med 121 (1994): 676-83. [PMID: 7944078]